Rivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy (RITE)

University Hospital Basel

Status: Completed

Conditions: Thromboembolism; Venous Thrombosis; Bleeding; Varicose Veins

Study type: Observational

Funder types: Other

Identifiers

NCT02584842

EKNZ 2014-346

Details and patient eligibility

About

The purpose of this study is to determine retrospectively if the application of rivaroxaban after endovenous laser ablation with and without miniphlebectomy is safe and if it lowers the risk of venous thrombosis.

Full description

Rivaroxaban is an orally active direct factor Xa inhibitor, that is used for thrombosis prophylaxis for example in the setting of orthopaedic surgery.

In the observed situation Rivaroxaban was applied in a dosage of 10mg daily during 5 days after endovenous laser ablation.

Enrollment: 400 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients age greater than 18 years, informed consent was given.
• Endovenous Laser Ablation (EVLA) of the greater saphenous vein (GSV), autologous saphenous vein (ASV) and/or small saphenous vein (SSV) using 1470 nm wavelength radial laser (ELVeS, Biolitec, Austria) and postinterventional Endothermal Heat Induced Thrombosis (EHIT) prophylaxis with rivaroxaban.

Exclusion criteria

Patients are ineligible if they had:

• an endovenous ablation technique other than EVLA,
• other veins than GSV, ASV or SSV treated with EVLA (i.e. perforators),
• postinterventional EHIT prophylaxis other than prophylactic dose of rivaroxaban or
• informed consent was not given.